Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Journey Medical Corp (DERM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/27/2025: DERM (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $12
1 Year Target Price $12
| 3 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 67.98% | Avg. Invested days 34 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 196.27M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 4 | Beta 0.79 | 52 Weeks Range 3.54 - 8.90 | Updated Date 10/26/2025 |
52 Weeks Range 3.54 - 8.90 | Updated Date 10/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.37 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.49% | Operating Margin (TTM) -19.16% |
Management Effectiveness
Return on Assets (TTM) -5.86% | Return on Equity (TTM) -57.22% |
Valuation
Trailing PE - | Forward PE 29.24 | Enterprise Value 197045861 | Price to Sales(TTM) 3.48 |
Enterprise Value 197045861 | Price to Sales(TTM) 3.48 | ||
Enterprise Value to Revenue 3.49 | Enterprise Value to EBITDA 17.72 | Shares Outstanding 20309844 | Shares Floating 12808299 |
Shares Outstanding 20309844 | Shares Floating 12808299 | ||
Percent Insiders 32.66 | Percent Institutions 33.36 |
Upturn AI SWOT
Journey Medical Corp
Company Overview
History and Background
Journey Medical Corp. was founded in 2014. It focuses on acquiring, developing, and commercializing dermatology products.
Core Business Areas
- Dermatology Products: Development and commercialization of prescription dermatology products for common skin conditions like acne, rosacea, and inflammatory skin diseases.
Leadership and Structure
Brent Beutlich is the Chairman of the Board, and Neal Cravens is the Chief Executive Officer. The company operates with a typical corporate structure, including departments like Research and Development, Sales and Marketing, and Finance.
Top Products and Market Share
Key Offerings
- Accutane: A branded isotretinoin product for severe acne. Competitors include generic isotretinoin products and alternative acne treatments. There is no direct market share data for this product, but isotretinoin products hold a significant portion of the severe acne market. Revenue contribution is significant. Key competitor: Sun Pharma
- Qbrexza: A topical anticholinergic cloth used to treat primary axillary hyperhidrosis (excessive underarm sweating). Competitors include other topical treatments, prescription antiperspirants, and Botox injections. There is no direct market share data for this product. Revenue contribution is significant. Key competitor: Brickell Biotech
Market Dynamics
Industry Overview
The dermatology market is growing, driven by factors like aging populations, increasing awareness of skin conditions, and the availability of new and innovative treatments.
Positioning
Journey Medical Corp. positions itself as a company focused on addressing unmet needs in the dermatology space. They aim to acquire and commercialize established brands, improve the patient experience, and maintain a competitive edge through brand recognition.
Total Addressable Market (TAM)
The global dermatology market is projected to reach hundreds of billions of dollars. Journey Medical is positioned to capture a share of this through established products and strategic acquisitions.
Upturn SWOT Analysis
Strengths
- Established product portfolio
- Experienced management team
- Focus on dermatology market
- Commercialization capabilities
Weaknesses
- High debt level
- Reliance on a limited number of products
- Exposure to generic competition
- Small company
Opportunities
- Acquisition of additional dermatology products
- Expansion into new geographic markets
- Development of new formulations
- Partnerships with other companies
Threats
- Generic erosion of key products
- Increased competition from other dermatology companies
- Regulatory changes
- Economic downturn affecting consumer spending
Competitors and Market Share
Key Competitors
- VRX
- MRK
- LLY
Competitive Landscape
Journey Medical Corp. faces competition from larger pharmaceutical companies with established dermatology portfolios and from generic manufacturers. Its advantages lie in its focus on dermatology and its ability to acquire and commercialize established brands.
Growth Trajectory and Initiatives
Historical Growth: Please refer to the company's SEC filings for up-to-date information.
Future Projections: Please refer to analyst reports for future growth projections.
Recent Initiatives: Please refer to the company's press releases for recent strategic initiatives.
Summary
Journey Medical Corp. is a small dermatology company focused on acquiring and commercializing products. Their strengths include an established portfolio and experienced management. However, they face challenges related to high debt, reliance on a few products, and competition from larger players. Future growth depends on successful acquisitions and navigating generic erosion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Market share figures are estimates and may not be precise. Consult a qualified financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Journey Medical Corp
Exchange NASDAQ | Headquaters Scottsdale, AZ, United States | ||
IPO Launch date 2021-11-12 | Founder, President, CEO & Director Mr. Claude Maraoui | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 41 | Website https://journeymedicalcorp.com |
Full time employees 41 | Website https://journeymedicalcorp.com | ||
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Emrosi for the treatment of inflammatory lesions of rosacea, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.